China-based oncology company BeiGene has raised a financing round of more than RMB450 million (approximately US$75 million) from a group of investors including CITIC Capital Partners, the private equity arm of CITIC Capital Holdings, and Asia-focused investment firm Hillhouse Capital. The round also included existing angel and strategic investors. BeiGene intends to use proceeds from the financing round for clinical development, with plans to bring two to three new drug candidates into the clinic in 2015, as well as for additional early-stage pipeline programs.